Delay in FTC approval for Aurobindo Pharma, Sandoz deal raises questions, says report
Updated : July 31, 2019 09:59 AM IST
Last year, Aurobindo had announced that it would acquire the commercial operations of Swiss drugmaker Novartis AGs’ generics unit in the US for $900 million.
the development comes a month after Aurobindo received a warning letter from the US Food and Drug Administration (FDA) for one of its units in Srikakulam.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more